SKB565 clinical trial: Why Kelun-Biotech’s first dual-payload ADC matters
Kelun-Biotech’s SKB565 gains China clinical trial clearance, moving its first dual-payload ADC toward a Phase 1/2 solid-tumor study.
Pharma & Biotech
Pharma & Biotech
Can Bio-Thera’s BAT8013 turn regulatory T-cell depletion into a workable solid-tumor strategy?
Bio-Thera has dosed the first patient in BAT8013’s Phase 1 trial. See why safety, Treg selectivity and dose choice will decide its future.
Pharma & Biotech
Ciprocopan China approval gives PNH patients a new once-daily oral Factor B treatment option
Nuvectis Pharma’s ciprocopan wins China approval for PNH. Read how the once-daily Factor B drug could reshape the global treatment race.
Pharma & Biotech
Zai Lab’s August 6 earnings could reveal whether its 2026 commercial reset is starting to work
Zai Lab reports Q2 2026 results on August 6 as investors assess revenue pressure, COBENFY and TIVDAK launches, and zoci pipeline progress.
Pharma & Biotech
Why Kelun-Biotech’s latest sac-TMT Phase III result could matter more than the headline suggests
Kelun-Biotech reports improved Phase III PFS with sac-TMT plus pembrolizumab, while survival and detailed safety data remain pending.
Pharma & Biotech
What the zemprocitinib enrollment milestone means for Lynk Pharmaceuticals’ late-stage pipeline
Lynk Pharmaceuticals completes Phase III zemprocitinib enrollment as ASAS40 efficacy, long-term safety and China filing tests move closer.
Pharma & Biotech
Leads Biolabs wins China priority review for opamtistomig in advanced EP-NEC
Nanjing Leads Biolabs Co., Ltd. has secured priority review in China for the biologics licence application covering opamtistomig as a monotherapy for advanced extrapulmonary neuroendocrine carcinoma after at least two previous systemic treatment lines. The July 10, 2026 decision moves the Hong Kong-listed biotechnology company, traded under stock code 9887, closer to a possible first
Pharma & Biotech
Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
Find out how Harbour BioMed’s HBM7004 China IND acceptance could reshape B7-H4 solid tumor immunotherapy development.
Pharma & Biotech
Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?
A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.
Pharma & Biotech
Lupin just cracked China with a flu drug. Why investors may want to look closer
Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.